• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多发性硬化症(MS)中的癌症风险:系统评价和荟萃分析。

Risk of cancer in multiple sclerosis (MS): A systematic review and meta-analysis.

机构信息

Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran.

Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran.

出版信息

Autoimmun Rev. 2020 Oct;19(10):102650. doi: 10.1016/j.autrev.2020.102650. Epub 2020 Aug 13.

DOI:10.1016/j.autrev.2020.102650
PMID:32801049
Abstract

OBJECTIVE

To assess the pooled risk of cancer in patients with multiple sclerosis.

METHODS

We searched PubMed, Scopus, EMBASE, Web of Science, Ovid, google scholar and gray literature (references of studies, conference abstracts) which were published up to September 2019. The search strategy included the MeSH and text words as ((cancer) OR tumor) OR neoplasm) OR "malignant neoplasm) OR "benign neoplasm) AND (Multiple Sclerosis OR Sclerosis, Multiple) OR Sclerosis, Disseminated) OR Disseminated Sclerosis) OR MS (Multiple Sclerosis)) OR Multiple Sclerosis, Acute Fulminating).

RESULTS

The first literature search revealed 18,996 articles. After deletion of duplicate articles, finally, 264 articles remained. Excluding non-relevant articles, resulted in including 5 articles which met inclusion criteria. The RR estimated between 0.7 and 1.67 in included articles. The pooled RR estimated as 0.83 (95% CI:0.73-0.96) (I = 90%, P < 0.001). Two studies provided prevalence of different cancers. The pooled prevalence of breast cancer in two studies was 2% (95%CI:2%-2%) (I = 0%). The pooled prevalence of digestive system cancer in two studies was 2% (95%CI:1%-2%) (I = 0%). The pooled prevalence of skin cancer in two studies was 1% (95%CI:0%-1%) (I = 0).

CONCLUSION

The result of this systematic review showed that the risk of cancer in patients with MS is less than the general population.

摘要

目的

评估多发性硬化症患者癌症的发病风险。

方法

我们检索了 PubMed、Scopus、EMBASE、Web of Science、Ovid、谷歌学术和灰色文献(研究参考文献、会议摘要),检索时间截至 2019 年 9 月。检索策略包括 MeSH 和文本词,如((癌症)或肿瘤)或新生物)或“恶性新生物)或“良性新生物)和(多发性硬化症或多发性硬化症)或硬化症,多发性)或播散性硬化症)或 MS (多发性硬化症))或多发性硬化症,急性暴发性)。

结果

第一次文献检索显示有 18996 篇文章。删除重复文章后,最终有 264 篇文章保留下来。排除不相关的文章后,有 5 篇文章符合纳入标准。纳入文章估计的 RR 值在 0.7 至 1.67 之间。汇总的 RR 估计值为 0.83(95%CI:0.73-0.96)(I = 90%,P < 0.001)。两项研究提供了不同癌症的患病率。两项研究中乳腺癌的汇总患病率为 2%(95%CI:2%-2%)(I = 0%)。两项研究中消化系统癌症的汇总患病率为 2%(95%CI:1%-2%)(I = 0%)。两项研究中皮肤癌的汇总患病率为 1%(95%CI:0%-1%)(I = 0%)。

结论

本系统评价的结果表明,多发性硬化症患者的癌症风险低于一般人群。

相似文献

1
Risk of cancer in multiple sclerosis (MS): A systematic review and meta-analysis.多发性硬化症(MS)中的癌症风险:系统评价和荟萃分析。
Autoimmun Rev. 2020 Oct;19(10):102650. doi: 10.1016/j.autrev.2020.102650. Epub 2020 Aug 13.
2
The prevalence of migraine in multiple sclerosis (MS): A systematic review and meta-analysis.多发性硬化症(MS)中偏头痛的患病率:系统评价和荟萃分析。
J Clin Neurosci. 2020 Sep;79:33-38. doi: 10.1016/j.jocn.2020.06.021. Epub 2020 Aug 4.
3
Prevalence of Sexual Dysfunction in Women with Multiple Sclerosis: a Systematic Review and Meta-Analysis.多发性硬化症女性性功能障碍的患病率:一项系统评价和荟萃分析。
Maedica (Bucur). 2019 Dec;14(4):408-412. doi: 10.26574/maedica.2019.14.4.408.
4
Prevalence of Seizure/Epilepsy in Patients with Multiple Sclerosis: A Systematic Review and Meta-Analysis.多发性硬化症患者癫痫发作/癫痫的患病率:一项系统评价和荟萃分析
Int J Prev Med. 2021 Feb 24;12:14. doi: 10.4103/ijpvm.IJPVM_75_20. eCollection 2021.
5
Prevalence of multiple sclerosis (MS) in Iran: a systematic review and meta-analysis.伊朗多发性硬化症(MS)的患病率:系统评价和荟萃分析。
Neurol Sci. 2022 Jan;43(1):233-241. doi: 10.1007/s10072-021-05750-w. Epub 2021 Nov 17.
6
Percutaneous posterior tibial nerve stimulation (PTNS) for lower urinary tract symptoms (LUTSs) treatment in patients with multiple sclerosis (MS): A systematic review and meta-analysis.经皮胫后神经刺激(PTNS)治疗多发性硬化症(MS)患者下尿路症状(LUTSs):系统评价和荟萃分析。
Mult Scler Relat Disord. 2022 Feb;58:103392. doi: 10.1016/j.msard.2021.103392. Epub 2021 Nov 10.
7
The Prevalence of Cancer in Patients with Multiple Sclerosis (MS) who were Under Treatment with Natalizumab (Tysabri): A Systematic Review and Meta-Analysis.接受那他珠单抗(泰萨比)治疗的多发性硬化症(MS)患者的癌症患病率:一项系统评价和荟萃分析。
Int J Prev Med. 2023 Sep 28;14:114. doi: 10.4103/ijpvm.ijpvm_77_22. eCollection 2023.
8
The prevalence of cancer in patients with multiple sclerosis (MS) who received rituximab: a systematic review and meta-analysis.接受利妥昔单抗治疗的多发性硬化症(MS)患者的癌症患病率:一项系统评价和荟萃分析。
Neurologia (Engl Ed). 2025 Jan-Feb;40(1):41-47. doi: 10.1016/j.nrleng.2022.07.004. Epub 2022 Aug 30.
9
Prevalence and risk of developing sexual dysfunction in women with multiple sclerosis (MS): a systematic review and meta-analysis.多发性硬化症(MS)女性性功能障碍的患病率和发病风险:系统评价和荟萃分析。
BMC Womens Health. 2023 Jul 4;23(1):352. doi: 10.1186/s12905-023-02501-1.
10
The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis.COVID-19 感染在多发性硬化症(MS)患者中的流行情况:系统评价和荟萃分析。
Neurol Sci. 2021 Aug;42(8):3093-3099. doi: 10.1007/s10072-021-05373-1. Epub 2021 Jun 7.

引用本文的文献

1
Exploring the role of sex hormones and gender diversity in multiple sclerosis.探索性激素和性别多样性在多发性硬化症中的作用。
Nat Rev Neurol. 2025 Jan;21(1):48-62. doi: 10.1038/s41582-024-01042-x. Epub 2024 Dec 11.
2
Drug Repurposing and Screening for Multiple Sclerosis Targeting Microglia and Macrophages.针对小胶质细胞和巨噬细胞的多发性硬化症药物再利用与筛选
Mol Neurobiol. 2025 Apr;62(4):4724-4742. doi: 10.1007/s12035-024-04602-w. Epub 2024 Nov 1.
3
Cancer and mortality risks among people with multiple sclerosis: A population-based study in Isfahan, Iran.
多发性硬化症患者的癌症和死亡率风险:伊朗伊斯法罕的一项基于人群的研究。
PLoS One. 2024 Oct 31;19(10):e0312707. doi: 10.1371/journal.pone.0312707. eCollection 2024.
4
Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.多发性硬化症患者的癌症风险:一项为期 10 年的全国回顾性队列研究。
Neurology. 2024 Nov 12;103(9):e209885. doi: 10.1212/WNL.0000000000209885. Epub 2024 Oct 9.
5
Association between multiple sclerosis and cancer risk: A two-sample Mendelian randomization study.多发性硬化症与癌症风险的关联:一项两样本孟德尔随机化研究。
PLoS One. 2024 Mar 19;19(3):e0298271. doi: 10.1371/journal.pone.0298271. eCollection 2024.
6
The Prevalence of Cancer in Patients with Multiple Sclerosis (MS) who were Under Treatment with Natalizumab (Tysabri): A Systematic Review and Meta-Analysis.接受那他珠单抗(泰萨比)治疗的多发性硬化症(MS)患者的癌症患病率:一项系统评价和荟萃分析。
Int J Prev Med. 2023 Sep 28;14:114. doi: 10.4103/ijpvm.ijpvm_77_22. eCollection 2023.
7
Positive Association Between the Immunogenetic Human Leukocyte Antigen (HLA) Profiles of Multiple Sclerosis and Brain Cancer.多发性硬化症与脑癌的免疫遗传人类白细胞抗原(HLA)谱之间的正相关关系。
Neurosci Insights. 2023 Dec 1;18:26331055231214543. doi: 10.1177/26331055231214543. eCollection 2023.
8
Is cancer risk reduced in multiple sclerosis? Results from a tertiary referral center.多发性硬化症是否降低癌症风险?来自三级转诊中心的结果。
Turk J Med Sci. 2023 Aug;53(4):962-969. doi: 10.55730/1300-0144.5660. Epub 2023 Aug 18.
9
The Prevalence of Inflammatory Bowel Disease (IBD) in Patients with Multiple Sclerosis (MS): A Systematic Review and Meta-Analysis.多发性硬化症(MS)患者中炎症性肠病(IBD)的患病率:一项系统评价和荟萃分析。
Int J Prev Med. 2023 Jun 22;14:81. doi: 10.4103/ijpvm.ijpvm_44_22. eCollection 2023.
10
Impact of aging on treatment considerations for multiple sclerosis patients.衰老对多发性硬化症患者治疗考量的影响。
Front Neurol. 2023 Jul 7;14:1197212. doi: 10.3389/fneur.2023.1197212. eCollection 2023.